1. Home
  2. GNTA vs CGTX Comparison

GNTA vs CGTX Comparison

Compare GNTA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genenta Science S.p.A.

GNTA

Genenta Science S.p.A.

SELL

Current Price

$0.68

Market Cap

31.8M

Sector

Health Care

ML Signal

SELL

CGTX

Cognition Therapeutics Inc.

BUY

Current Price

$0.73

Market Cap

79.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
GNTA
CGTX
Founded
2014
2007
Country
Italy
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.8M
79.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
GNTA
CGTX
Price
$0.68
$0.73
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
51.7K
★ 470.3K
Earning Date
03-24-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 62.79
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$0.55
52 Week High
$10.00
$1.93

Technical Indicators

Market Signals
Indicator
GNTA
CGTX
Relative Strength Index (RSI) 36.62 22.27
Support Level $0.59 $0.55
Resistance Level $0.76 $1.18
Average True Range (ATR) 0.06 0.06
MACD 0.01 -0.02
Stochastic Oscillator 0.05 4.23

Price Performance

Historical Comparison
GNTA
CGTX

About GNTA Genenta Science S.p.A.

Genenta Science SPA is an industrial consolidator focused on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its acquisition activities span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity, with a focus on businesses covered by Italy's Golden Power legislation.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: